In vivo metabolic studies of the trans-(R,R) isomer of radioiodinated IQNP: a new ligand with high affinity for the M1 muscarinic-cholinergic receptor

In this paper we describe the results of metabolic studies of E-(R,R)-IQNP directed at determining the metabolic fate of this ligand and the identification of the radioactive species observed in the brain and heart tissue. Tissue Folch extracts demonstrated that the lipid-soluble extracts from brain contained 87.0%±1.65% of the activity up to 24 h. In the heart, 61.9%±7.50% of the activity was extracted in the lipid-soluble extract after 30 min, decreasing to 51.4%±0.65% by 4 h. In contrast, data from other tissues studied demonstrated large amounts of either aqueous soluble activity or activity which was not extracted from the tissue pellet material; analysis of lipid organic extracts revealed the following results: liver (4 h), 7.43%±0.96%; serum (4 h), 3.73%±0.87%; urine (24 h), 9.4%; feces (24 h), 16.5%. Thin-layer chromatographic (TLC) and high-performance liquid chromatographic (HPLC) analyses of lipid-soluble brain extracts indicated that only unmetabolized E-(R,R)-IQNP was detected (99.4%±1.25%). Activity which was extracted into the organic phase from heart tissue was also determined by TLC and HPLC analysis to contain large amounts of unmetabolized ligand after 4 h (88.5%±0.57%). In addition, however, low levels of two additional radioactive components were detected which increased with time. TLC analysis of the plasma lipid extracts indicated only a small amount of unmetabolized E-(R,R)-IQNP. In comparison, the liver, feces, and urine lipid extracts contained only metabolites. These initial studies clearly indicate that radioactivity present in the brain after intravenous administration of radioiodinated E-(R,R)-IQNP represents only the unmetabolized ligand and that this new ligand shows promise for single-photon emission tomographic imaging of muscarinic receptors in humans. (orig.)